Beam Therapeutics Inc. Proceeds from Common Stock Issued
Beam Therapeutics Inc. (BEAM) reported Proceeds from Common Stock Issued of $236.57 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-02-25
- Beam Therapeutics Inc. proceeds from issuance of common stock for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Beam Therapeutics Inc. proceeds from issuance of common stock for the quarter ending 2023-09-30 was $34.95M.
- Beam Therapeutics Inc. proceeds from issuance of common stock for the quarter ending 2023-06-30 was $107.64M, a 381.36% increase year-over-year.
- Beam Therapeutics Inc. proceeds from issuance of common stock for the quarter ending 2023-03-31 was $93.98M, a 74.03% increase year-over-year.
- Beam Therapeutics Inc. proceeds from issuance of common stock for fiscal 2023 was $236.57M, a 118.52% increase from fiscal 2022.
- Beam Therapeutics Inc. proceeds from issuance of common stock for fiscal 2022 was $108.26M, a 85.71% decline from fiscal 2021.
- Beam Therapeutics Inc. proceeds from issuance of common stock for fiscal 2021 was $757.45M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $34.95M derived: sum of 2 quarters · filed 2025-02-25 | $142.59M derived: sum of 3 quarters · filed 2025-02-25 | $236.57M 10-K · filed 2025-02-25 |
| 2023-09-30 | $34.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $142.59M derived: sum of 2 quarters · filed 2024-11-05 | $236.57M 10-Q · filed 2024-11-05 | $268.46M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $107.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $201.62M 10-Q · filed 2024-08-06 | $233.52M derived: sum of 3 quarters · filed 2025-02-25 | $233.52M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $93.98M 10-Q · filed 2024-05-07 | $125.87M derived: sum of 2 quarters · filed 2025-02-25 | $125.87M derived: sum of 3 quarters · filed 2025-02-25 | $148.24M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $31.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $31.89M derived: sum of 2 quarters · filed 2025-02-25 | $54.26M derived: sum of 3 quarters · filed 2025-02-25 | $108.26M 10-K · filed 2025-02-25 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $22.36M derived: sum of 2 quarters · filed 2023-11-08 | $76.36M 10-Q · filed 2023-11-08 | $96.61M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $22.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $76.36M 10-Q · filed 2023-08-08 | $96.61M derived: sum of 3 quarters · filed 2024-02-27 | $415.53M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $54.00M 10-Q · filed 2023-05-10 | $74.25M derived: sum of 2 quarters · filed 2024-02-27 | $393.17M derived: sum of 3 quarters · filed 2024-02-27 | $551.45M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $20.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $339.17M derived: sum of 2 quarters · filed 2024-02-27 | $497.45M derived: sum of 3 quarters · filed 2024-02-27 | $757.45M 10-K · filed 2024-02-27 |
| 2021-09-30 | $318.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $477.20M derived: sum of 2 quarters · filed 2022-11-07 | $737.21M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $158.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $418.28M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $260.00M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |